Vaccines based on replication-defective adenoviral vectors are being developed for infectious agents and tumorassociated antigens. Early work focused on vaccines derived from a common human serotype of adenovirus, that is, adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies against AdHu5 virus, present in a large percentage of the human population, dampen the efficacy of vaccines based on this carrier. To circumvent this problem, we generated vectors derived from chimpanzee adenoviruses.
Introduction
Recombinant adenoviruses (Ad), originally used as vehicles for gene replacement therapy, 1 have become favorite vaccine carriers for delivery of genes derived from pathogens [2] [3] [4] or tumors. 5 They elicit strong and sustained transgene product-specific immune responses upon delivery of a single dose given either systemically 6, 7 or via mucosal routes. 8 On a practical note Ad vectors developed to date accommodate comparatively large pieces of foreign DNA, they can be grown to high titer in available cell lines, and methods for purification and scale-up production are well established, which facilitates their development for clinical use. Most of the past efforts focused on human Ads, such as those of the common serotype 5 (AdHu5), which cause mild upper respiratory symptoms upon natural infections. Both replication competent 9, 10 and E1-deleted (DE1) replication-defective AdHu5 vectors have been developed as vaccine carriers and have shown efficacy in mice, 11 dogs 12, 13 and nonhuman primates (NHPs). 7 E1-deleted AdHu5 vectors also performed well in clinical trials. 14 A substantial portion of human adults carries virusneutralizing antibodies to AdHu5 virus due to previous natural infection. In the US about 45% of the adult human population has significant titers of virus neutralizing antibodies to AdHu5 virus 15 and this percentage is comparable in Africa and even higher in Asia. As was demonstrated in experimental animals and subsequently in human volunteers, virus-neutralizing antibodies (VNAs) to AdHu5 virus reduce the potency of AdHu5-based vaccines. 6, 16 VNAs block cell entry by Ad vectors, which is a prerequisite for synthesis of the transgene product. We addressed the critical problem of pre-existing immunity on the efficacy of Ad-based vaccine carriers by developing vectors derived from chimpanzee-origin Ad viruses termed AdC68 and AdC7 or Pan9 and Pan7, respectively. [15] [16] [17] These vaccine carriers are based on molecular clones 18 thereby circumventing risks associated with potential contamination of the vaccines with unidentified pathogens of simian origin. AdC68 and AdC7 do not circulate in the human population. 15 VNAs to AdC68 partially neutralize AdC7 and vice versa. Both viruses are closely related to human serotype 4 Ad. 15 AdC68 and AdC7 vectors, similar to AdHu5 vectors, induce potent transgene product-specific CD8 + T-cell and B-cell responses. 6, 16 Transgene productspecific B-cell responses elicited by the chimpanzeeorigin vectors are not impaired by pre-existing immunity to common human serotypes of adenovirus. 16 CD8 + T-cell responses are slightly reduced and this reduction seems to be caused by CD8 + T cells directed to conserved sequences of Ad. 6 Similar to AdHu5 virus, AdC7 and AdC68 viruses gain entry into cells through the coxsackie adenovirus receptor (CAR) and thus are expected to have a similar tropism to the well-studied AdHu5 virus. 19 For clinical development, reproducible production of sufficient amounts of high-quality vectors that are genetically stable, show acceptable batch reproducibility and, in case of DE1Ad vectors, lack contamination with replication competent adenovirus (RCA), arising upon recombination of the vectors with the E1 gene present in the packaging cell line, is crucial. DE1AdC68 and DE1AdC7 vectors are trans-complemented by the E1 of AdHu5 virus. 15 The E1-flanking sequences differ between AdHu5 and the simian-origin viruses, which prevents homologous recombination and outgrowth of RCAs in DE1AdC68 or DE1AdC7 vector batches. For expression of large transgenes, deletions in addition to E1 such as of E3, which encodes immunoevasion polypeptides 20 that are nonessential for viral growth or E4, an essential region that has to be trans-complemented by the packaging cell line, 21 are needed. Such deletions may affect vector performance.
Here, we tested parameters of replication-defective AdC68 and AdC7 vectors that may affect their performance as vaccine carriers. Specifically we tested for batch variation in vector infectivity and how this affects the vectors' ability to induce transgene product-specific CD8 + T-cell responses. We also assessed the effect of different deletions and variations in insert length on vector performance. Lastly, we compared SIV-1 antigenspecific CD8 + T-cell responses induced by a polypeptide vaccine expressing a SIV-gag-pol-nef fusion protein to those elicited by a vaccine incorporating a mixture of adenovirus vectors individually expressing SIV-1 gag, pol and nef.
Results
Vector yield, contamination with RCA, infectivity and batch reproducibility Moving experimental vaccine constructs into the clinic requires that they can be readily propagated to levels that allow for eventual large-scale production. In the case of DE1Ad vectors, lack of contamination with RCAs (arising from homologous recombination with the E1 of the packaging cell line) is also essential. (Figure 1 ). To determine if the insert length affected vector yields or infectivity of the vector preparations, we compared 9-10 AdC68 vectors carrying small transgenes ranging in size from 300 to 1600 bp to those carrying large inserts of 4500 to 5000 bp. Although as shown in Table 2 vectors with small inserts tended to give higher yield and lower vp-to-PFU ratios, the differences were statistically not significant.
Stimulation of transgene product-specific CD8 + T cells is driven by peptides derived from de novo synthesized protein, requiring infectivity of the vector. To address the role of relative vector infectivity, we compared DE1/ E3AdC68SIVgag-pol-nef vector batches with a vp-to-PFU ratio of 1:200 to a batch with a high vp-to-PFU ratio of 1:2480. C57Bl/6 mice were immunized intramuscularly with graded doses of vector and frequencies of splenic CD8 + T cells to the immunodominant epitope of gag were measured 10 days later by intracellular cytokine staining (ICS). As shown in Figure 2a The table shows the arithmetic mean7standard deviations (and the range in parenthesis) for vector yields and vp-to-PFU ratios for E1 or E1 and E3 deleted AdC68 vectors. Vectors carried transgenes ranging in size from B300 to 1600 bps (E7 of HPV-16, glycoprotein gene of rabies virus, gag of HIV-1 and SIV, n ¼ 9) or from B4400-5300 bps (SIV or HIV-1gag-pol or gag-pol-nef fusion genes, n ¼ 10). Statistical significance for differences in yields and infectivity were calculated by Student's t-test (P-value for yields: 0.077, P-value for infectivity: 0.31). Chimpanzee-origin adenovirus vectors N Tatsis et al showed low infectivity, was needed to achieve by day 10 frequencies of gag-specific CD8 + T cells comparable to those induced by the batch that had an infectivity to vp ratio of 1:200. As toxicity of replication-defective Ad vectors, which is primarily mediated by proinflammatory cytokines released rapidly in response to the capsid proteins of Ad, is linked to vp rather than infectious units, the tendency of the AdC7 vectors to have lower yields of infectious particles may be of concern for their eventual clinical development. Nevertheless, it should be pointed out that most vector batches had ranges of vp to PFU (Figure 1 ) that did not affect induction of transgene product-specific CD8 + T cells. To assess reproducibility of vector performances (a prerequisite for their use as vaccine carriers), three different batches derived independently from the same stock of DE1/E3AdC68SIVgag-pol vectors were tested. Comparable frequencies of gag epitope-specific CD8 + T cells were achieved (Figure 2b) . A parallel experiment using DE1/E3AdC7SIVgag-pol vectors yielded similar results (Figure 2c ). It should be pointed out that vectors used for these experiments had vp-to-PFU ratios that showed at most a four-fold difference.
Effects of deletions of adenoviral genes on vector performance
For complex pathogens, such as HIV-1, which shows a high degree of sequence variability between different isolates and rapidly mutates upon infection of an individual, a vaccine has to induce an immune response of sufficient breadth. This requires induction of T cells to several viral antigens to allow for protection against wild-type strains of virus and to limit outgrowth of escape mutants upon infection. Accommodation of large sequences such as those of multiple antigens either as fusion proteins or as individual antigens into the genome of Ad vectors requires deletions in addition to E1. DE1Ad vectors accommodate B3.5 kb of sequence, DE1/E3Ad vectors can carry B7 kb of foreign sequence and further deletion of E4 increases the permitted insert size by an additional 3 kb. The effects of these different deletions have been studied in depth for AdHu5 vectors, but their impact on gene transfer by simian Ad vectors remains unclear. To determine whether additional deletions of the simian Ad backbone influence levels of transgene product expression, we transduced CHO cells stably expressing CAR with simian Ad vectors expressing a humanized, C-terminus truncated form of HIV gag (termed gag37) 24 under the control of the early promoter of cytomegalovirus. Ad vectors used in these experiments were deleted in E1 alone, E1 and E3 or in E1, E3, and E4 ( Figure 3a) . As shown, the E3 deletion did not have an effect on transgene product production while deletion of E4 decreased protein expression from both AdHu5 and AdC68 vectors. CD8 + T-cell responses to gag were also reduced when the E4-deleted vectors were used to immunize BALB/c mice (Figure 3b and c) . The reduction in T-cell frequencies was most pronounced at the lower doses. Vectors deleted in E4 cannot be tested for plaque formation on HEK 293 cells and the poor performance of such vectors may in part reflect low contents of infectious particles. Alternatively, physiological functions of E4 polypeptides (which even in E1-deleted vectors are expected to be produced at albeit only low levels) may facilitate adaptive immune responses to the transgene product.
The consequence of the overall size of the Ad genome was also assessed. To adjust the size of the Ad vector genome, we tested a DE1/E3AdC68HIVgag37+S vector in which 2500 bp of stuffer sequences had been added. The frequencies of splenic transgene product-specific CD8 + T cells in response to the different vectors, which were assessed in BALB/c mice vaccinated with different doses of vectors, showed that at moderate doses of 10 10 and 10 9 vp DE1AdC68HIVgag37 and DE1/E3AdC68HIV-gag37 vectors induced comparable frequencies of gagspecific CD8 + T cells. Addition of stuffer sequences to adjust the genome size had no effect (Figure 3d ). The E3 region of adenoviruses encodes polypeptides that serve the virus to evade T-cell-mediated destruction of infected cells by reducing expression of major histocompatibility complex (MHC) class I determinants, by inhibiting TAPmediated peptide transport into the ER, by blocking fas-mediated apoptosis and the TNF signaling pathways. 25 Circumventing the reduction of expression of Chimpanzee-origin adenovirus vectors N Tatsis et al CD8 + T-cell epitopes on MHC class I antigens through deletion of E3 would be expected to increase activation of CD8 + T-cell responses. However, the E1 deletion, which renders Ad vectors replication-defective, also strongly reduces transcription of all other viral genes. Levels of E3 polypeptides encoded for by DE1 vectors are hence unlikely to be sufficiently high to influence perceptibly induction of transgene product-specific CD8 + T cells.
Vectors deleted in E1 or E1 and E3 expressing a truncated envelope protein of HIV-1 Clade B, that is, gp140, were also compared. Incorporation of the E3 deletion in addition to E1 for both the AdC68 and AdC7 vectors facilitated incorporation of larger transgenes, such as HIV-1 gp140, but CD8 + T-cell responses to gp140 antigen were similar in both DE1 and DE1/E3 vectors (not shown).
Effect of transgene length on protein expression and CD8
+ T-cell responses
As described above, for some pathogens including HIV-1, vaccines will have to be developed that express multiple antigens. Ad vectors deleted in E1 and E3 accommodate B7 kb of foreign sequence which suffices to insert gag, pol and nef designed as a fusion gene together with needed regulatory sequences. Alternatively, one could mix vectors expressing individual antigens. The latter would require a dose reduction for each individual vector to accommodate dose-limiting toxicity related to the vaccine carrier. It would also require more cumbersome preclinical toxicity testing prior to phase I trials. Overall, logistically a minimal number of vectors expressing the largest possible amount of foreign sequence would be desirable; nevertheless, the effect of insert length on the ability of simian Ad vectors to induce transgene product-specific CD8 + T-cell has not yet been established. We tested for this by initially comparing simian Ad vectors expressing SIVmac 239 antigens of different lengths. Ad vectors expressing gag, pol and nef or gag and pol as fusion proteins were compared to Ad vectors expressing gag alone for transgene product expression levels and for induction of gag-specific CD8 + T-cell frequencies in mice. As shown in Figure 4a , levels of protein expression were markedly higher when gag was expressed as an individual antigen. Accordingly, the DE1AdC68SIVgag vector induced higher frequencies of transgene product-specific CD8 + T cells compared to DE1/E3AdC68SIVgag-pol or DE1/E3Ad-C68SIVgag-pol-nef vectors (Figure 4b ).
To extend our T-cell analyses to epitopes other than the one carried by gag we defined CD8 + T-cell epitopes of SIV pol and nef in BALB/c and C57Bl/6 mice. To this end, groups of BALB/c and C57Bl/6 mice were immunized with Ad vectors expressing either gag, pol or nef and splenocytes were tested 14 days later for IFN-g Table 3 .
To further assess induction of CD8 + T cells by simian Ad vectors expressing gag-pol-nef as a polypeptide or as individual proteins, groups of C57Bl/6 Â BALB/c F1 mice were vaccinated with graded doses of the DE1/ E3AdC68SIVgag-pol-nef vector or mixtures of the three individual AdC68 vectors expressing the same sequences as individual proteins, that is, DE1AdC68SIVgag, DE1/ E3AdC68SIVpol and DE1AdC68SIVnef. Vector doses within the mixture were adjusted so that each vector was present at an equal concentration and the final dose of vector (in vp) per mouse equaled that of the polypeptide vaccine. Frequencies of splenic CD8 + T cells to individual epitopes of gag, pol and nef were tested 14 days later. No response could be detected to nef (not shown). As shown in Figure 4c and d, the mixture of vectors expressing individual antigens induced by far higher frequencies of transgene product-specific CD8 + T-cell compared to the polypeptide vaccine even though the final dose of each individual vector in this mixture was only one-third of the dose of the vector expressing the polypeptide.
To test if frequencies of CD8 + T cells to individual epitopes were affected if mice were injected with mixtures of Ad vectors, groups of BALB/c mice were injected with a mixture of four AdC68 vectors expressing antigens of HIV-1. The codon-humanized sequences includes those encoding gp140 of HIV-1 clade B, gag, the N-terminal 650 amino acids of pol of HIV-1 clade B and a construct expressing a modified clade B nef fused at the C-terminus with the remaining 368 amino acids of pol. In this construct, the fusion protein contains a TPA leader sequence fused to the N-terminus of nef. In one group of mice, the vectors designated DE1/ E3AdC68HIVgp140, DE1AdC68HIVgag, DE1/E3Ad-C68HIV5 0 pol, DE1/E3AdC68HIVTPAnef-3 0 pol were mixed at equal ratios and injected together. In another group, the DE1/E3AdC68HIVgp140 was mixed with the DE1/E3AdC68HIVTPAnef-3 0 pol vector and the DE1Ad-C68HIVgag vector was mixed with the DE1/E3Ad-C68HIV5 0 pol vector and the two mixtures were injected separately into the left or right quadriceps muscles. Additional groups of mice were injected with only one of the vectors. In this experiment, the dose of each individual vector was kept constant and each mouse received 2.5 Â 10 10 vp of each AdC68 vectors. Responses were tested for by ICS using peptides carrying previously defined epitopes or epitopes that were identified as described above for the SIV antigens ( Table 2) . As shown in Figure 5b , the effect of mixing vectors expressing different transgene products on frequencies of transgene product-specific CD8 + T cells was largely dependent on the epitope; responses to one of the pol epitopes (AA357-371) were not affected by using mixtures of vector. In contrast, CD8 + T-cell frequencies to the other three epitopes, that is, one additional epitope of pol (AA941-955), one epitope of gag (AA197-205) and one epitope of env (311-320), were markedly higher in mice injected with only the corresponding vector. Application of a mixture of four vectors into one leg versus application of 2 Â 2 vectors into different sites resulted in comparable frequencies.
Discussion
Results of experiments presented in this paper were designed to test the performance of simian replication- Figure 5 Mixtures of vectors. BALB/c mice (three per group) were immunized with a mixture of DE1AdC68HIVgag, DE1/E3Ad-C68HIV5 0 pol, DE1/E3AdC68HIVTPAnef-3 0 pol and DE1/E3Ad-C68HIVgp140. Each vector was given at 2.5 Â 10 10 vp per mouse. Vectors were either mixed and injected together (mix of four vectors); DE1AdC68HIVgag was mixed with DE1/E3Ad-C68HIV5 0 pol and DE1/E3AdC68HIVTPAnef-3 0 pol was mixed with DE1/E3AdC68HIVgp140 and the two mixtures were injected separately into the right and left quadriceps of mice (mixture of 2 Â 2 vectors) or mice were injected with one of the four vectors only (single vectors). Frequencies of transgene product-specific CD8 + T cells were determined by ICS 10 days later from spleens of individual mice. *Represents P-value o0.05 comparing frequencies against a given epitope comparing single vectors with vector mixtures.
Chimpanzee-origin adenovirus vectors N Tatsis et al defective Ad vectors as gene transfer vectors for viral antigens especially those derived from pathogens such as HIV-1 for which vaccine-induced protection will rely at least in part on CD8 + T cells. Neutralizing antibodies, the correlate of vaccine-induced protection against most viral infections, that broadly cross-neutralize HIV-1 isolates, cannot currently be induced by vaccines. 26, 27 It is assumed based on preclinical studies with SIV that HIV-1 specific T cells will not provide sterilizing immunity or allow for complete clearance of HIV-1 but rather lower the set point viral load and thus reduce morbidity and further spread of the virus. As HIV-1 rapidly mutates in infected hosts, the vaccine-induced CD8 + T-cell response has to be of sufficient breadth to prevent outgrowth of escape mutants. A number of different vaccine carriers have been tested preclinically as well as in part clinically for induction of CD8 + T-cell responses to HIV-1.
28-33
Here we compared simian Ad vectors that varied with regard to deletions and insert lengths to determine which types of constructs are most suitable for further clinical development. DE1AdC68 and DE1/E3AdC68 vectors showed favorable growth characteristics and yields commonly exceeded those of AdHu5 vectors. The ratios of infectious to noninfectious particles in AdC68 vectors were comparable to those obtained with AdHu5 vectors. In contrast, AdC7 vectors had, in general higher vp-to-PFU ratios. The effect of deletions in E4 was tested. Deletion of E4 could potentially be advantageous; DE4Ad vectors produce less late gene products compared to E1 only deleted vectors and thus reduce induction of vector-specific immune responses and provide less targets for T cells directed to cross-reactive antigens of Ad. Such T cells present in humans with immunological memory to related human serotypes of Ad virus could potentially affect the efficacy of simian Ad vectors. Furthermore, deletion of E4 minimizes outgrowth of replication-competent virus in packaging cell lines, although this is not a major concern for simianorigin Ad vectors grown on packaging cell lines containing the E1 of AdHu5 virus. Previous gene therapy trials reported that deletion or functional inactivation of E4 in AdHu5 vectors reduces the inflammatory response to the vector, 34 and decreases AdHu5-mediated upregulation of adhesion molecules in endothelial cells. 35 Such adhesion molecules are crucial for lymphocyte trafficking. Furthermore, E4 has been reported to affect the performance of viral and cellular promoters. 36 E4 polypeptides have multiple additional functions that may influence the performance of Ad vectors as vaccine carriers. Overall, simian Ad vectors deleted in E4 performed poorly; they showed a decrease in transgene product expression and induced lower frequencies of transgene product-specific CD8 + T cells compared to DE1/E3 Ad vectors unless used at high doses.
The length of the insert had the most dramatic effect on performance of the simian Ad vectors expressing antigens of SIVmac239. DE1/E3AdC68SIVgag-polnef and DE1/E3AdC68SIVgag-pol vectors express low levels of antigen and induce only marginal frequencies of transgene product-specific CD8+ T-cell responses when compared to the E1-only deleted vector. Thus although the use of an Ad vector vaccine expressing multiple antigens of SIV/HIV-1 has clear logistic advantages, the poor immunogenicity of such constructs precludes their further development as vaccines. Using mixtures of vectors reduces the magnitude of the CD8 + T-cell response to some of the transgene product. This result was expected and is likely to reflect competition of peptides for the MHC class I peptide binding site. The reduction, although reproducible, is comparatively modest compared to the very strong reduction of the response to vectors expressing the HIV/SIV antigens as long polypeptides. This indicates that for an HIV-1 vaccine where multiple antigens must be expressed, mixtures of simian Ad vectors that achieve high levels of antigen expression should be pursued for clinical development. Single vectors carrying long fusion genes produce less antigen which adversely effects their performance as CD8 + T-cell inducers. In summary, simian Ad vectors are being developed as vaccines for HIV-1. Results presented here show that DE1AdC68 and DE1/E3AdC68 vectors have favorable growth characteristics. DE1 or DE1/E3AdC68 vectors expressing individual antigens or fusion polypeptides of moderate length used as mixtures perform well in small animal immunogenicity studies. This warrants their further exploration for eventual clinical testing.
Materials and methods
Cell culture and virus production CHO/CAR cells (most kindly provided by J Bergelson, Children's Hospital, University of Pennsylvania, Philadelphia, PA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS, 0.1 mM MEM nonessential amino acids, 1 mM Na pyruvate, 2 mM L-glutamine, 10 mM HEPES, Pen/Strep and Gentamicin in a 10% CO 2 371C incubator. HEK 293 cells were propagated in DMEM supplemented with the same reagents but for HEPES buffer and cultured in a 5% CO 2 incubator. Adenoviral vectors were generated from molecular clones, propagated, purified and quality controlled (PFU-to-vp ratios, RCA content, genome integrity) as described elsewhere. 11, 15 Inserts: clade B SIVgag, SIVgag-pol, SIVgag-pol-nef, SIVpol, SIVnef, HIVgp140 and HIVgag were generous gifts from G Nabel at the NIH/VRC, Bethesda, MD, USA. HIVgag37 was a generous gift from G Pavlakis at the NIH/NCI, Fredrick, MD. The HIV5 0 pol contains amino acids 1-650 of clade B HIV-1 pol and the HIVTPAnef-3 0 pol contains a TPA leader sequence fused to clade B HIV-1 nef fused to the C-terminal 368 amino acids of HIV-1 pol. Both HIV5 0 pol and TPAnef-3 0 pol were synthesized in codonoptimized forms by Geneart.
Mice
Female BALB/c, C57Bl/6, and (BALB/c Â C57Bl/6)F1 mice were purchased at 6-8 weeks of age from Charles River, Jackson Laboratories or Ace Laboratories and housed in the Wistar Institute Animal Facility. Animals were treated according to institutional rules for animal welfare.
Protein expression analysis
For immunoblots 1 Â 10 6 CHO/CAR cells were plated in 6 cm wells and infected with adenoviruses in 500 ml serum-free DMEM for 2 h at 371C in a 10% CO 2 incubator. They were then supplemented with 2 ml Chimpanzee-origin adenovirus vectors N Tatsis et al 10% DMEM and cultured for an additional 36 h. Ad was added at either 1000 or 100 virus vp/cell as indicated. After the incubation time, the cells were washed 1 Â with phosphate-buffered saline (PBS) containing Ca 2+ and Mg 2+ and then incubated on ice for 10 min in hypotonic buffer (10 mM TrisHCl pH8, 5 mM KCl, 2 mM MgCl 2 and 100 mM phenyl methyl sulfonyl fluoride (PMSF)). Cells were then scraped into iced microfuge tubes and pulled through a 28 G needle 4-5 Â , then spun in a microfuge for 5 min at 12 000 r.p.m. Cell lysates were collected and a Bradford assay was performed to measure total protein recovered. Lysates were boiled for 5 min in Laemmli sample buffer and equal amounts of total protein were loaded onto a 12% PAGE gel. Proteins in the gel were transferred onto PVDF membrane and protein was detected by immunoblot. Antibodies used were 183-H12-5C (NIH AIDS Research and Reference Reagent Program) for HIV-1 Gag at 1:2000 and anti-mouse HRP (Roche) at 1:12 500, for SIV Gag pooled serum from SIV mac251 -infected monkeys (MRC AIDS Directed Program) was used at a 1:200 dilution and anti-monkey HRP at a 1:1000 dilution. All incubations and washes were in PBS+0.1%Tween 20; for incubation with the 11 antibody 3% BSA was added. Detection was through luminol reagent Western Lightening (Perkin Elmer).
Intracellular cytokine staining
Splenocytes (1 Â 10 6 /sample) were cultured for 5 h at 371C in 96-well round bottom microtiter plate wells in DMEM supplemented with 2% FBS and 10 À6 M 2-ME. Brefeldin A (GolgiPlug; BD PharMingen, San Diego, CA, USA) was added at 1 ml/ml. In general, peptides were used for CD8 + T-cell stimulation in vitro at a concentration of 1-3 mg/ml. Control cells were incubated with an unrelated peptide or without peptide. After washing, cells were incubated for 30 min at 41C with 25 ml of a 1/100 dilution of a FITC-labeled Ab to mouse CD8 (BD PharMingen). They were washed again and permeabilized in 1 Â Cytofix/Cytoperm (BD PharMingen) for 20 min at 41C, washed two times with Perm/Wash (BD PharMingen), and incubated in the same buffer for 30 min at 41C with 25 ml of a 1/100 dilution of a PElabeled Ab to mouse IFN-g (BD PharMingen). After washing, cells were examined by two-color flow cytometry using an EPICS Elite XL (Beckman Coulter, Miami, FL, USA), and data were analyzed by WinMDi software. Cells incubated without the specific peptide showed o0.5% PE staining of CD8 + T cells (data not shown). Data for most experiments, each of which is representative for data obtained in 2-4 separately conducted experiments, reflect the mean frequencies derived from lymphocytes of spleens of 3-5 individual mice in standard deviations (s.d.) of the mean.
